Enliven Therapeutics (ELVN) Other Working Capital Changes (2019)

Enliven Therapeutics (ELVN) has 1 years of Other Working Capital Changes data on file, last reported at -$369000.0 in Q4 2019.

• For the quarter ending Q1 2026, Other Working Capital Changes fell 40.58% year-over-year to -$97000.0; the trailing twelve-month figure through Mar 2026 stood at -$365000.0 (down 13.71% YoY), and the FY2025 full-year result was -$337000.0, down 0.6% from the prior year.
• Other Working Capital Changes eased to -$97000.0 in Q1 2026, from -$91000.0 in the prior quarter.
• In the past five years, Other Working Capital Changes ranged from a high of $1000.0 in Q4 2022 to a low of -$229000.0 in Q3 2023.
• A 5-year average of -$77000.0 and a median of -$83500.0 in 2024 frame the typical range for Other Working Capital Changes.
• Peak annual rise in Other Working Capital Changes reached 63.32% in 2024, while the deepest fall reached 8200.0% in 2024.
• Tracing ELVN's Other Working Capital Changes over 5 years: stood at $1000.0 in 2022, then sank by 8000.0% to -$79000.0 in 2023, then decreased by 7.59% to -$85000.0 in 2024, then declined by 7.06% to -$91000.0 in 2025, then fell by 6.59% to -$97000.0 in 2026.
• Business Quant data shows ELVN's Other Working Capital Changes at -$97000.0 in Q1 2026, -$91000.0 in Q4 2025, and -$90000.0 in Q3 2025.